美股异动丨减肥药概念股上涨，礼来涨超5%创新高

Group 1 - The core viewpoint of the article highlights the significant rise in obesity drug concept stocks, with Eli Lilly's stock increasing over 5%, reaching a new high [1] - Novo Nordisk has officially launched the world's first oral GLP-1 medication for adult weight loss in the United States [1] - Eli Lilly is reportedly in advanced negotiations to acquire Ventyx Biosciences for over $1 billion, focusing on a drug in mid-development for treating obesity-related cardiovascular diseases [1] Group 2 - Amgen's stock rose over 3%, while Roche and Novo Nordisk saw increases of 2.4% and 1.9%, respectively [1]